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GABA(A) receptors as in vivo substrate for the anxiolytic action
of valerenic acid, a major constituent of valerian root extracts
Abstract
Valerian extracts have been used for centuries to alleviate restlessness and anxiety albeit with unknown
mechanism of action in vivo. We now describe a specific binding site on GABA(A) receptors with nM
affinity for valerenic acid and valerenol, common constituents of valerian. Both agents enhanced the
response to GABA at multiple types of recombinant GABA(A) receptors. A point mutation in the beta2
or beta3 subunit (N265M) of recombinant receptors strongly reduced the drug response. In vivo,
valerenic acid and valerenol exerted anxiolytic activity with high potencies in the elevated plus maze
and the light/dark choice test in wild type mice. In beta3 (N265M) point-mutated mice the anxiolytic
activity of valerenic acid was absent. Thus, neurons expressing beta3 containing GABA(A) receptors
are a major cellular substrate for the anxiolytic action of valerian extracts.
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Abstract 
Valerian extracts have been used for centuries to alleviate restlessness and anxiety 
albeit with unknown mechanism of action in vivo. We now describe a specific binding 
site on GABAA receptors with nM affinity for valerenic acid and valerenol, common 
constituents of valerian. Both agents enhanced the response to GABA at multiple 
types of recombinant GABAA receptors. A point mutation in the β2 or β3 subunit 
(N265M) of recombinant receptors strongly reduced the drug response. In vivo, 
valerenic acid and valerenol exerted anxiolytic activity with high potencies in the 
elevated plus maze and the light/dark choice test in wild type mice. In β3 (N265M) 
point-mutated mice the anxiolytic activity of valerenic acid was absent. Thus, neurons 
expressing β3 containing GABAA receptors are a major cellular substrate for the 
anxiolytic action of valerian extracts.  
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1. Introduction 
Various extracts from the roots of plants of the genus Valeriana (Valerianaceae) are 
used in herbal medicine of many cultures as mild sedatives and tranquilizers. 
Valerenic acid is a main constituent of Valeriana officinalis, most widely used in 
Europe and USA. In animal experiments, valerenic acid or extracts from valerian 
showed tranquilizing and/or sedative activity (Bent et al., 2006; De Feo and Faro, 
2003; Hendriks et al., 1985). Activation of adenosine receptors has been implicated 
in the action of valerian ingredients (Müller et al., 2002; Schumacher et al., 2002). 
Valerenic acid was also shown to modulate or - at high concentrations - activate 
GABAA receptors as shown for recombinant receptors expressed in Xenopus oocytes 
(Khom et al., 2007) or neonatal brainstem neurons (Yuan et al., 2004). However, the 
molecular mechanism of action of any of the valerian ingredients in vivo is yet 
unknown. We have now identified a specific binding site for valerenic acid and 
valerenol, common constituents of valerian, on GABAA receptors. In addition, it was 
demonstrated that valerenic acid mediates anxiolytic activity via GABAA receptors 
containing the β3 subunit. Mice containing a single amino acid point mutation in the β3 
subunit [β3(N265M)] failed to show anxiolytic activity to valerenic acid, but maintained 
an anxiolytic response to diazepam. 
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2. Materials and Methods 
2.1. Chemicals 
Valerenic acid was purchased from Extrasynthese, Lyon (France). TTX was 
purchased from Alomone labs (Israel). All other chemicals were from Sigma-Aldrich 
(Switzerland). The α1 subunit-specific antibody is described in Benke et al. (1991). 
 
2.2. Synthesis of valerenic acid derivatives 
Valerenol (2), valerenal (3), and O-methyl-valerenol (4) were synthesized according 
to Scheme S1. 
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Scheme S1: i. LiAlH4, THF, rt, 2h, 92%. ii. (COCl)2, DMSO, Et3N, CH2Cl2, -78°C→ 
RT, 30 min, 89%. iii. CH3I, NaH, ether, -78°C→ RT, 84%.    
 
2.2.1. Valerenol (2) 
Valerenic acid (1) (275 mg, 1.17 mmol, 1 eq) was dissolved in THF (10 ml) under Ar. 
A 1 M solution of LiAlH4 in THF was then added (1.1 ml, 1.1 mmol, 1 eq) and the 
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reaction mixture was stirred at room temperature for 2 h. The reaction was quenched 
with diluted aq H2SO4 and extracted with diethyl ether. The organic phase was dried 
over Na2SO4 and concentrated in vacuo. The resulting crude product was purified by 
flash chromatography (FC) in AcOEt/hexane ¼, yielding 238 mg (92%) of Valerenol 
(2) as colourless oil. AcOEt = ethyl acetate. 
Rf (AcOEt/hexane 1/4): 0.36 (vanilline/H2SO4) 1H-NMR (500 MHz, CDCl3): 5.75 (d, J 
= 9.3 Hz, 1H), 4.01 (s, 2H), 3.46 (dd, J1 = 4.9 Hz, J2 = 8.5 Hz, 1H), 2.94-2.92 (m, 1H), 
2.20 (t, J = 7.6 Hz, 2H), 1.97-1.96 (m, 1H), 1.89-1.76 (m, 3H), 1.73 (s, 3H), 1.65 (s, 
3H), 1.59-1.49 (m, 1H), 1.40-1.27 (m, 2H), 0.77 (d, J = 7.0 Hz, 3H). 13C-NMR (125 
MHz, CDCl3): 147.5, 135.1, 133.0, 129.1, 69.2, 47.3, 37.4, 33.4, 33.1, 26.1, 24.5, 
28.5, 13.7, 13.5, 12.0. 
 
2.2.2. Valerenal (3) 
A solution of oxalyl chloride (9 μl, 0.102 mmol, 1.5 eq) in CH2Cl2 (0.5 ml) under Ar 
was cooled to -78° and DMSO (7.5 μl, 0.102 mmol, 1.5 eq) was added. After 15 min 
a solution of valerenol (2) (15 mg, 0.068 mmol, 1 eq) in CH2Cl2 (0.1 ml) was added 
followed by triethylamine (125 μl, 0.340 mmol, 5 eq.; after 15 additional min). The 
cooling bath was removed after 5 min and stirring was continued at room 
temperature for 30 min. Then the reaction was quenched with water and the mixture 
extracted with diethylether. The organic layer was separated, dried over Na2SO4, and 
concentrated in vacuo. The resulting crude product was purified by FC 
(ether/pentane 1/10), yielding 13.3 mg (89%) of Valerenal (3) as a colourless oil. 
Rf (ether/pentane 1/2): 0.39 (vanillin/H2SO4). 1H-NMR (500 MHz, CDCl3): 9.38 (s, 
1H), 6.75 (qd, J1 = 9.8 Hz, J2 = 1.3Hz, 1H), 3.74-3.69 (m, 1H), 2.92-2.98 (m, 1H), 
2.24-2.19 (t, J = 7.4 Hz, 2H), 2.06-1.97 (m, 1H), 1.89-1.81 (m, 3H), 1.80 (d, J = 1.3 
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Hz, 3H), 1.65 (s, 3H), 1.61-1.53 (m, 1H), 1.50-1.42 (m, 2H), 0.80 (d, J = 7.3 Hz, 3H). 
13C-NMR(125 MHz, CDCl3): 195.9, 156.1, 139.9, 137.3, 132.4, 47.3, 37.2, 34.5, 32.7, 
28.6, 25.0, 24.3, 13.4, 11.7, 9.1. 
 
2.2.3. O-Methyl valerenol (4) 
To a solution of valerenol (2) (19 mg, 0.09 mmol, 1 eq) in diethylether (1 ml) was 
added sodium hydride (2.3 mg, 0.10 mmol,1.1 eq) at -78°C under Ar. After 15 min 
methyl iodide (6 µl, 0.10 mmol, 1.1 eq) was added and the mixture stirred at room 
temperature for 1 h. The reaction was then quenched with water and extracted with 
diethylether. The organic layer was separated, dried over Na2SO4, and concentrated 
in vacuo. The crude product was purified by FC (AcOEt/hexane 1/10), yielding 16 mg 
(84%) of O-methylvalerenol (4) as a colourless oil. Rf (AcOEt/hexane 1/10): 0.76 
(vanillin/H2SO4). 1H-NMR (500 MHz, CDCl3): 5.73 (dq, J1 = 9.1 Hz, J2 = 1.3 Hz, 1H), 
3.83-3.76 (m, 2H), 3.48-3.43 (m, 1H), 3.28 (s, 3H), 2.96-2.89 (m, 1H), 2.19 (t, J = 7.6 
Hz, 2H), 2.00-1.92 (m, 1H), 1.88-1.77 (m, 2H), 1.75-1.67 (m, 1H), 1.70 (d, J = 7.6 Hz, 
3H), 1.65-1.63 (m, 3H),1.57-1.50 (m, 1H), 1.40-1.34 (m, 2H), 0.77 (d, J = 6.9 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): 135.1, 130.2, 129.8, 129.0, 78.9, 57.2, 47.3, 37.4, 33.3, 
33.2, 28.6, 26.2, 24.5, 13.7, 13.2, 12.0. 
 
2.3. Preparation of crude neuronal membranes 
Crude membranes were prepared from adult rat brain tissue. Following 
homogenization in 10 volumes of 10 mM Tris-HCl, pH 7.4, 0.32 M sucrose, 5 mM 
EDTA, 0.1 mM phenylmethylsulfonyl fluoride and centrifugation at 1000 g for 10 min 
the resulting supernatant was centrifuged for 20 min at 12,000 g to obtain the crude 
membrane pellet. The crude membranes were resuspended in buffer and stored at -
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80°C until used. For [3H]valerenic, [3H]flunitrazepam and [3H]flumazenil binding, 
crude membrane were thawed and washed three times in 50 mM Tris pH 7.4. For 
[3H]muscimol binding, crude membranes were resuspended in 20-40 volumes of 5 
mM Tris-HCl 7.4, frozen in liquid nitrogen, thawed and centrifuged for 20 min at 
45,000 g. This procedure to eliminate endogenous GABA was repeated two times. 
Radioligand binding using [3H]muscimol, [3H]flunitrazepam and [3H]flumazenil was 
performed as described previously (Benke et al., 1991). 
 
2.4. [3H]Valerenic binding assay 
To establish a radioligand binding assay, valerenic acid was custom-labeled by 
tritium using random catalytic exchange of hydrogen by tritium (6.5 Ci/mmol; RC 
Tritec, Teufen, Switzerland). For [3H]valerenic acid binding, crude rat brain 
membranes were washed three times in 50 mM Tris-HCl pH 7.4 and incubated (200 
μg protein) with 300 nM [3H]valerenic acid in a total volume of 0.2 ml for 45 min at 
room temperature. Subsequently, the reactions were filtered though glass microfiber 
filters and washed with ice cold buffer (50 mM Tris-HCl pH 7.4). Filters were then 
processed for liquid scintillation counting using a Tricarb 2500 liquid scintillation 
analyzer. Non-specific binding was assessed in parallel by coincubation with 100 μM 
unlabelled valerenic acid. Binding of [3H]valerenic acid (300 nM) to well-washed 
membranes increased linearly with the protein concentration up to 1.5 mg/ml. 
Equilibrium of binding was reached after 20 min at room temperature (measured at 
50 and 300 nM [3H]valerenic acid and 200 μg protein). Saturation binding 
experiments were performed with 3 - 600 nM [3H]valerenic acid and 200 μg protein 
per assay. Binding data were analyzed using the programs Kell (Biosoft, UK) and 
GraphPad Prism 4.0 (GraphPad Software, USA). 
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 2.5. Immunoprecipitation 
Crude membranes prepared from rat brain tissue were washed once with 10 mM 
Tris-HCl pH 8, 150 mM NaCl, 1 mM EDTA, 200 mg/l bacitracin, 0.1 mM 
phenylmethylsulfonyl fluoride, 2.3 mg/l aprotinin, 1 mM benzamidine and 
resuspended in the same buffer to a protein concentration of 5 mg/ml followed by 
addition of sodium deoxycholate to a final concentration of 0.5%. After incubation for 
30 min at 4°C, insoluble material was removed by centrifugation for 30 min at 
100,000 g. For immunoprecipitation of GABAA receptors, aliquots (0.5 ml) of the 
deoxycholate extract were incubated with α1-subunit-selective antiserum overnight at 
4°C (Benke et al. 1991). Receptor-antibody complexes were precipitated by 
incubation with 50 μl of protein A-agarose for 60 min. After extensive washing, the 
precipitates were resuspended in 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 200 mg/l bacitracin, 0.1 mM phenylmethylsulfonyl fluoride, 2.3 mg/l aprotinin, 
1 mM benzamidine, 0.2% Triton X-100 and subjected to radioligand binding 
experiments using 300 nM [3H]valerenic acid (see above), 6 nM [3H]flumazenil and 
10 nM [3H]Ro 15-4513 as described previously (Benke et al., 1991). 
 
2.6. cDNAs and site-directed mutagenesis 
Rat α1, α2, α3, α4, α5, β2, β3 and γ2s GABAA receptor subunit cDNAs were used and 
transferred in human embryonic kidney cells (HEK) as described previously (Siegwart 
et al. 2002). For the β3 subunit, site-directed mutagenesis substituting an asparagine 
residue at position 265 with a methionine residue, β2(N265M) and β3(N265M) was 
perfomed as described (Siegwart et al., 2002; 2003). 
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2.7. Electrophysiology 
Current recordings from recombinant GABAA receptors in HEK 293 cells were 
performed using the whole cell patch-clamp technique as described previously 
(Benson et al., 1998). Primary cultures of hippocampal neurons were prepared from 
wild type E18 rat brain (van Rijnsoever et al., 2005) and whole cell voltage-clamp 
recordings were made using standard techniques (Hamill et al., 1981). Briefly: 
Cultures were continuously superfused with ACSF containing (in mM: 125 NaCl, 26 
NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 1 MgCl2, 2.5 CaCl2, and 11 glucose, oxygenated 
with 95% O2-5% CO2), TTX was added to block Na channels and APV (100 uM) and 
NBQX (20 uM) were added to isolate miniature inhibitory postsynaptic currents 
(mIPSCs). Whole cell voltage-clamp recordings of spontaneous mIPSCs from 
pyramidal cells were obtained at room temperature with a holding potential of –60 
mV and a high chloride containing internal solution (in mM: 100 CsCl, 2 MgCl2, 1 
EGTA, 2 ATP, 0.3 GTP, and 40 HEPES, pH 7,2, 300 mOsm). 
 
2.8. Mutant mice 
The generation and breeding of homozygous mutant mice containing a (N265M) 
mutation in the GABAA receptor β3 subunit was performed as described previously 
(Jurd et al., 2003). 
 
2.9. Behavioral tests 
The anxiolytic drug action was tested in the light/dark choice test and in the elevated 
plus maze test as described (Löw et al., 2000; Rudolph et al., 1999). The animals 
were maintained on a 12:12 h reversed light–dark cycle, with ad libitum food and 
water. All manipulations described here had been approved by the Cantonal 
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Veterinary Office of Zurich; they conformed to the ethical standards required by the 
Swiss Act and Ordinance on Animal Protection and the European Council Directive 
86/609/EEC. 
 
2.10. Statistics 
Data are expressed as mean ± SEM or mean ± SD as indicated in the legend to the 
figure. If required, data were analyzed for statistical significance using the test 
indicated in the respective figure legend. P values less than 0.05 were considered 
significant. 
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3. Results 
3.1. Allosteric interaction of valerenic acid with the GABA and benzodiazepine 
binding site 
Using radioligand binding, we aimed at identifying the binding site for valerenic acid. 
In a first set of experiments the potential interaction of valerenic acid with the 
benzodiazepine and GABA binding site was analyzed. [3H]Flumazenil, 
[3H]flunitrazepam and [3H]muscimol binding to crude rat brain membranes was dose-
dependently increased by valerenic acid to a maximum of 200-500% with EC50 
values of 23 ± 1 μM, 7 ± 1 μM and 42 ± 6 μM, respectively (Fig. 1). Valerenol also 
potentiated benzodiazepine binding to GABAA receptors with an EC50 of 16 ± 7 μM 
as tested in the [3H]flunitrazepam binding assay (not shown). These results indicate 
that valerenic acid and valerenol allosterically interact with the benzodiazepine and 
GABA binding sites of GABAA receptors. 
 
3.2. [3H]Valerenic acid binding 
To directly assess the valerenic acid binding site of GABAA receptors, valerenic acid 
was radiolabeled by random catalytic exchange of hydrogen by tritium. [3H]Valerenic 
acid binding to brain membranes revealed both a high affinity binding site (KD = 25 ± 
20 nM) and a low affinity site (KD = 16 ± 10 μM). [3H]Valerenic acid was displaced not 
only by valerenic acid but also by valerenol with even higher potency (IC50 = 3 ± 2 
nM, Tab. 1). A 1000 fold lower displacing potency was found for hydroxy-valerenic 
acid whereas O-methyl valerenol, valerenal and valeric acid (each at 100 μM) were 
completely inactive (Tab. 1). 
To verify that GABAA receptors indeed harbour the binding site for [3H]valerenic acid, 
GABAA receptors were immunoprecipitated from deoxycholate extracts of rat brain 
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membranes using an antibody directed against the α1 subunit. Radioligand binding 
to the well-washed immunoprecipitates demonstrated that the valerenic acid binding 
site was coimmunoprecipitated with the classical benzodiazepine sites as 
demonstrated by the specific [3H]flumazenil, [3H]Ro 15-4513 and [3H]valerenic acid 
binding to the precipitate (Fig. 2). Thus, high affinity [3H]valerenic acid binding sites 
are located on GABAA receptors. 
To test whether the [3H]valerenic acid binding site corresponds to any of the well 
established modulatory binding sites of the GABAA receptor, competition experiments 
were performed. Ligands for the GABA (THIP, SR95531), benzodiazepine 
(flunitrazepam), barbiturate (phenobarbital), channel blocker (picrotoxinin) and the 
loreclezole site (each up to 100 μM) did not affect [3H]valerenic acid binding (not 
shown). However, [3H]valerenic acid binding was enhanced in the presence of 
propofol (680 ± 126%), etomidate (190 ± 21%) and alphaxolon (200 ± 19%), 
suggesting an allosteric interaction with sites for these anaesthetics (Tab. 2). The 
anti-inflammatory agent mefenamic acid, which shares structural similarities with 
loreclezole and etomidate (Halliwell et al., 1999), was found to inhibit [3H]valerenic 
acid binding with an IC50 of 7 ± 3 μM. These results suggest that valerenic acid may 
bind to a previously unrecognized site on GABAA receptors that is allosterically linked 
to sites for anaesthetics and mefenamic acid. 
 
3.3. Effect of valerenic acid of recombinant receptors expressed in HEK 293 cells 
Valerenic acid was recently shown to enhance the GABA-induced chloride currents 
of recombinant GABAA receptors expressed in Xenopus oocytes (Khom et al. 2007). 
Here we used a different expression system (HEK 293 cells) to confirm a positive 
allosteric potentiation of valerenic acid on recombinant GABAA receptors. On GABAA 
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receptors expressed in HEK 293 cells, valerenic acid strongly enhanced a 
submaximal GABA response (EC10 at 3 μM) as demonstrated for GABAA receptors 
comprising the subunits α1β2γ2 (EC50 = 5.6 ± 0.6 μM), α2β2γ2 (11.8 ± 0.9 μM), α3β2γ2 
(8.1 ± 1.3 μM) and α5β2γ2 (8.6 ± 1.8 μM) with similar Hill coefficients (Hill 1.7 ± 0.2; 
1.6 ± 0.2; 1.7 ± 0.4; 1.7 ± 0.5 respectively) (Fig. 3A). The GABA response at α2β3γ2 
was likewise enhanced by valerenic acid as tested at 10 μM (Fig. 3D). Valerenic acid 
(10 μM) enhanced the GABA response also at α4β2γ2 receptors (350 ± 50 % of 
control) while diazepam but not bretazenil (Benson et al. 1998) was inactive (Fig. 
3B). 
In the absence of GABA, there was no direct activation of GABAA receptors by 10 μM 
valerenic acid as tested at α1β2γ2 receptors (not shown). However, at high 
concentrations of valerenic acid (≥ 30 μM ) a direct activation of α1β2γ2 receptors was 
previously observed (Khom et al., 2007). 
At α1β2 GABAA receptors, valerenic acid (up to 50 μM) failed to enhance the GABA 
response, while alphaxolone and propofol (each at 10 μM) retained their potentiating 
activity (Fig. 3C).  
Valerenol, a congener of valerenic acid, likewise enhanced the GABA response as 
tested at α2β3γ2 receptors (Fig. 3D). However, structurally different compounds such 
as valeric acid, valeric anhydride, valeronitrile, δ-valerolactame and γ- or δ- 
valerolactone (each at 10 μM) failed to alter the GABA response as measured at 
α1β2γ2 receptors (not shown).  
Asparagine 265 in the β2 subunit was suggested to play an important role for the 
potentiating effect of valerenic acid based on its mutation to serine (Khom et al., 
2007). We used β2 and β3 subunit cDNAs in which the asparagine residue 265 was 
mutated to methionine (Siegwart et al., 2002). When recombinant GABAA receptors 
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were expressed in HEK 293 cells in the subunit combination α1β2(N265M)γ2 or 
α2β3(N265M)γ2, the ability of valerenic acid to enhance the GABA response was 
strongly diminished (Fig. 3D). In addition, the GABA potentiating effect of valerenol 
(10 μM) was likewise strongly reduced as tested in α2β3(N265M)γ2 receptors 
compared to the corresponding wildtype receptor (Fig. 3D). This result suggests that 
the integrity of the valerenic acid binding site or the transduction of the GABA 
potentiating effect is impaired when the N265M mutation is present in either the β2 or 
β3 subunit.  
 
3.4. Potentiation of synaptic GABAergic responses by valerenic acid 
Valerian extracts and valerenic acid are known to reduce the discharge rate in 
muscimol-sensitive brainstem neurons of neonatal rats (Yuan et al., 2004). However, 
it was not clear whether valerenic acid would enhance the amplitude or the kinetics of 
the GABAA receptor response. Whole cell patch clamping experiments were 
therefore performed on cultured hippocampal neurons and miniature inhibitory 
postsynaptic currents (mIPSP) were measured. In analogy to the effects on 
recombinant GABAA receptors, the synaptic GABAergic response in hippocampal 
neurons was enhanced by valerenic acid as shown by an increase of the peak 
amplitude of the GABAergic mIPSCs from 37.5 ± 4.8 pA to 53.1 ± 4.5 pA (mean ± 
SEM, n=7, p<0.01) without an apparent change in kinetics (Fig. 4A, B). These results 
demonstrate that valerenic acid potentiates the GABA responses of synaptic GABAA 
receptors in situ. 
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3.5. The anxiolytic activity of valerenic acid is mediated by GABAA receptors 
containing the β3 subunit 
To assess the relevance of GABAA receptors in mediating the effects of valerenic 
acid in vivo, the anxiolytic activity was chosen as pharmacodynamic parameter. In 
the light/dark choice test, valerenic acid (1, 3 and 6 mg/kg i.p. or 10 mg/kg po) 
showed a significant effect by decreasing the aversion of wildtype mice to the lit area 
(Fig. 5 A, C). Valerenol (1, 10, 30 mg/kg i.p. or 1, 10 mg/kg po) likewise decreased 
the aversion to the lit area in the light dark test (Fig. 5 B, D). The anxiolytic activity of 
valerenic acid (10 mg/kg po) was also demonstrated in the elevated plus maze by the 
enhancement of the time spent on the open arms (Fig. 5E). There was no indication 
for sedation induced by valerenic acid (10 mg/kg po and 30 mg/kg i.p.) as tested by 
analyzing locomotor activity in an actimeter for at least 1 hour (not shown). Thus, 
higher receptor occupancy may be required for the sedative effect of valerenic acid 
compared to its anxiolytic action. 
To verify that the anxiolytic action of valerenic acid was exclusively mediated via 
GABAA receptors in vivo and not by yet unknown targets, the compound was tested 
in mice containing the N265M point mutation in the β3 subunit gene of GABAA 
receptors. In the β3(N265M) mice, in contrast to wild type mice, valerenic acid (3 
mg/kg i.p.) failed to show anxiolytic-like activity in the light/dark test (Fig. 5 F). After 
oral administration, valerenic acid (10 mg/kg) likewise displayed strongly reduced 
anxiolytic-like activity in this test in the β3(N265M) mice compared to controls (not 
shown). As a control, it had to be verified that the β3(N265M) mutation would not 
interfere with the animals principal ability to display an anxiolytic-like response to a 
GABAA receptor drug. When diazepam (1.5 mg/kg i.p.) was tested in the β3(N265M) 
mice, it retained its anxiolytic activity as shown by the significantly increased time 
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spent in the lit area in the light/dark test (Fig. 5 F). Thus, the point mutation (N265M) 
in the β3 subunit of GABAA receptors is sufficient to completely prevent the ability of 
valerenic acid to display anxiolytic-like activity in vivo. This result strongly argues for 
β3 subunit containing GABAA receptors to be the molecular target for the anxiolytic-
like action of valerenic acid. By implication, neuronal circuits expressing β3 
containing GABAA receptors qualify as cellular targets.  
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4. Discussion 
GABAA receptors containing the β3 subunit have been identified as the major target 
which mediates the anxiolytic action of valerenic acid, a major constituent of valerian 
root extracts. This result is based on several lines of evidence. 
1. By [3H]valerenic acid binding to brain membranes, a novel site was discovered 
which displayed high nM affinity for valerenic acid and valerenol but not for 
structurally close derivatives for valerenic acid. This binding site was located on 
GABAA receptors as shown by the enhancement of [3H]valerenic acid binding by 
certain GABAA receptor ligands. In addition, when GABAA receptors were 
solubilized and immunoprecipitated with anti-α1 subunit antibodies, [3H]valerenic 
acid binding was enriched in the immunoprecipitate. Judging by the ligand 
selectivity, the binding site appeared to differ from the known drug modulatory sites 
on GABAA receptors. Valerenic acid enhanced radioligand binding to the 
benzodiazepine and GABA site, while [3H]valerenic acid binding was potentiated 
by anesthetics like propofol, etomidate and alphaxolon, indicating an allosteric 
interaction with these sites. The only drug acting tested that inhibited [3H]valerenic 
acid binding was the anti-inflammatory agent mefenamic acid, albeit only at μM 
concentrations. Mefenamic acid shares structural similarities with loreclezole and 
etomidate and was suggested to interact with the same or overlapping sites 
(Halliwell et al., 1999). Therefore, the valerenic acid and merfenamic acid binding 
sites may be overlapping or allosterically linked.  
2. Valerenic acid and valerenol were shown to act as positive allosteric modulators of 
GABAA receptors as demonstrated for both recombinant receptors and receptors in 
situ. On recombinant receptors (Fig. 3) valerenic acid acted as positive allosteric 
modulator not only on the classical benzodiazepine-sensitive GABAA receptors, 
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characterized by the α1, α2, α3 or α5 subunit, but differed from classical 
benzodiazepines in that valerenic acid enhanced the action of GABA also on 
α4β2γ2 receptors. These results confirm previous findings on recombinant receptors 
of Khom et al. (2007). On α1β2 receptors, valerenic acid (up to 50 μM) failed to 
potentiate the GABA response. This finding is at variance with the observation of a 
potentiation (EC50 = 5.2 ± 2.4 μM) of the GABA response by valerenic acid as 
tested on α1β2 receptors expressed in Xenopus oocytes (Khom et al., 2007). 
Although this discrepancy is presently unexplained, it is not of major relevance in 
the present context, since αβ receptors are a negligible complement of GABAA 
receptors in vivo. The lack of response of valerenic acid in our experiments in HEK 
293 cells (Fig. 3D) is not due to a failure of α1β2 receptor expression, since, as 
expected, propofol and alphaxolone potentiated the GABA response at α1β2 
receptors (Fig. 3C).  
3. The β2(N265M) and the β3(N265M) point mutation inhibited the GABA potentiating 
effect of valerenic acid on recombinant receptors. This result implies that it is the β 
subunit in the β2 or β3 GABAA receptors which determines the activity of valerenic 
acid. This result does not necessarily imply that the binding site of valerenic acid 
includes the residue in position 265. The β2(N265M) and the β3(N265M) point 
mutations are known to impair to various degrees the effects of diverse drugs such 
loreclezole, propofol or etomidate (for review Rudolph and Antkowiak, 2004). Thus, 
the point mutation may interfere with drug binding and/or with signal transduction 
within the GABAA receptor complex. 
4. The results on recombinant receptors were substantiated by whole cell current 
recordings in hippocampal neurons in culture. Valerenic acid significantly 
enhanced the peak amplitude of the GABA-induced current without apparent 
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changes in current kinetics (Fig. 4). This result is in keeping with the ability of 
valerenic acid (100 μM) to enhance the effect of muscimol in rat brain stem 
neurons (Yuan et al. 2004). In hippocampal CA1 pyramidal cell somata, the fast 
phasic currents in hippocampal CA1 pyramidal cell somata are known to be 
predominantly mediated by α2 GABAA receptors (Prenosil et al., 2006). Thus, the 
hippocampal neuronal somatic response to valerenic acid was most likely due to 
an enhancement of α2 GABAA receptors. 
5. In order to elucidate the mechanism of action of valerenic acid in vivo, it was 
necessary to ascertain that the in vivo activity was indeed mediated via GABAA 
receptors and not by another yet unknown target. Therefore, the anxiolytic activity 
of valerenic acid was determined in vivo in wild type mice in comparison to 
β3(N265M) mice. This mutant mouse strain was chosen based on prior experience. 
On recombinant receptors, both the β2(N265M) and the β3(N265M) mutation 
strongly reduced the activity of valerenic acid and of valerenol (Fig. 3D). However, 
judging by the response of diverse GABAA receptor drugs tested previously on 
β2(N265M) or β3(N265M) mutant mice, the β3(N265M) mutation generally showed 
a stronger differentiation of drug responses than the β2(N265M) strain in vivo 
compared to wild type (Rudolph and Antkowiak, 2004). Therefore, the mutant mice 
containing the β3(N265M) point mutation were chosen for the analysis of the 
mechanism of action of valerenic acid in vivo. In the light/dark choice test, an 
anxiolytic activity was demonstrated for valerenic acid administered either i.p. or po 
(Fig. 5A,C) as well as for valerenol (Fig. 5B,D) at a potency comparable to that of 
diazepam in this test (Löw et al., 2000) Similarly, valerenic acid (10 mg/kg p.o.) 
showed anxiolytic activity in the elevated plus maze test, as shown by the 
significant increase in the time spent on the open arm (Fig. 5E). Most importantly, 
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valerenic acid failed to display anxiolytic activity in mice containing the β3(N265M) 
mutation as tested in the light/dark choice test (Fig. 5F) in a concentration which 
produced a robust response in wildtype mice (Fig. 5A). The failure of the 
β3(N265M) mice to display the anti-aversive activity of valerenic acid treatment is 
not due to the inability of the point mutated animals to perform in this test. When 
the β3(N265M) mutants were treated with diazepam, a clear anti-aversive effect of 
the drug was apparent (Fig. 5F). At recombinant receptors containing the 
β3(N265M) mutation, valerenic acid displayed a weak residual activity (Fig. 3D). 
This finding is not reflected in vivo, where the anxiolytic effect of valerenic acid was 
absent in the β3(N265M) mutant mice, suggesting that the anxiolytic response in 
wild type animals occurs at a low receptor occupancy. Furthermore, the lack of an 
anxiolytic response of valerenic acid in the (β3N265M) mice suggests that GABAA 
receptors containing the β2 subunit do not play a major role for the anxiolytic 
activity of valerenic acid. Thus, neurons expressing GABAA receptors containing 
the β3 subunit are major mediators of the anxiolytic activity of valerenic acid. 
Previously, the anxiolytic activity of benzodiazepines has been shown to be 
mediated via α2 GABAA receptors (Löw et al., 2000). These receptors largely 
contain β3 subunits in addition to a γ2 subunit. Thus, benzodiazepines and 
valerenic acid share, at least in part, a common anxiolytic molecular and cellular 
substrate in those neuronal circuits which express α2β3γ2 GABAA receptors.  
 
Valerenic acid amounts up to about 2% of valerian extracts and was found in 
commercial preparations at a mean concentration of 3.5 mg/g powder capsules with 
the highest values of 6.3 mg/g. (Shohet et al., 2001; Gao and Björk, 2000). The 
potency of valerenic acid in two widely used anxiolytic animal test models (Fig. 4A,E) 
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was comparable to that of diazepam (Löw et al., 2000). Assuming that the 
pharmacokinetic properties in man are likewise comparable to diazepam, the daily 
dose of valerenic acid can be expected to be sufficient to induce anxiolytic activity. 
Valerenic acid is the main constituent in valerian extracts to convey an enhancement 
of GABAA receptors (Trauner et al., 2008). Thus, valerenic acid and valerenol would 
largely account for the anxiolytic action of valerian extracts.  
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Table 1.  Inhibiton of [3H]valerenic acid binding. 
 
Drug IC50 μM) n 
Valerenol 0.003 ± 0.002 5 
Hydroxy valerenic acid 61 ± 19 3 
O-Methyl valerenol >100 2 
Valerenal >100 2 
Valeric acid >100 2 
 
The potencies of various agents in inhibiting binding of [3H]valerenic acid were 
determined by incubating rat brain membranes with [3H]valerenic acid (300 nM) in the 
presence of increasing concentrations of the respective compounds. Nonspecific 
binding was determined in the presence of excess cold valerenic acid. Data 
represent the mean ± SD of the indicated number (n) of independent experiments. 
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Figure legends 
Fig. 1.  Valerenic acid increases radioligand binding to the benzodiazepine and 
GABA binding site. Well washed rat brain membranes were incubated with 
increasing concentrations of valerenic acid in the presence of [3H]flunitrazepam (0.5 
nM), [3H]flumazenil (0.25 nM) and [3H]muscimol (10 nM), respectively. Nonspecific 
binding was determined by co-incubation with clonazepam (10 μM) for 
[3H]flunitrazepam and [3H]flumazenil binding or with GABA (100 μM) for [3H]muscimol 
binding. Data represent the mean ± SEM of three independent experiments. 
 
Fig. 2.  Co-immunoprecipitation of [3H]Valerenic acid binding sites with GABAA 
receptors. GABAA receptors were immunoprecipitated from solubilized rat brain 
membranes using α1 subunit-selective antibodies and probed for the presence of 
[3H]valerenic acid (300 nM), [3H]flumazenil (6 nM) and [3H]Ro 15-4513 (10 nM) 
binding. Data represent the mean ± SD of three independent experiments. 
 
Fig. 3.  Effect of valerenic acid and valerenol on whole cell currents of HEK 293 cells 
expressing the indicated GABAA receptor subunit combinations. (A) Valerenic acid 
potentiated GABA-induced currents (3 μM) in HEK 293 cells expressing the subunit 
combination α1β2γ2 (EC50=5.6 ± 0.6 μM, nH=1.7 ± 0.2) α2β2γ2 (EC50=11.8 ± 0.9 μM, 
nH=1.6 ± 0.2), α3β2γ2 (EC50=8.1 ± 1.3 μM, nH=1.7 ± 0.4) and α5β2γ2 (EC50=8.6 ± 1.8 
μM, nH=1.7 ± 0.5). Data represent the mean peak currents ± SEM (n=4-8). Error bars 
smaller than the symbol are not shown. Data were fitted using the equation: Enhanc 
(y) = 1/{1+(EC50/[Valerenic])Hill}. (B) Valerenic acid (10 μM) and bretazenil (10 μM), 
but not diazepam (1 μM), increased GABA-activated currents (3 μM) of α4β2γ2 
receptors. Data represent the mean peak currents ± SEM (n=4-8). (C) GABA-
 26
activated currents (3 μM) at α1β2 receptors were potentiated by propofol (10 μM) and 
alphaxalone (10 μM), but not by valerenic acid (5-50 μM). Data represent the mean 
peak currents ± SEM (n=4-8). (D) Recombinant receptors containing the N265M 
mutation in the β2 or β3 subunit displayed a strongly reduced sensitivity to the 
modulatory effects of valerenic acid and valerenol (3 μM GABA for α1β2γ2, α2β3γ2; 7 
μM GABA for α1β2[N265M]γ2, α2β3[N265M]γ2). Data represent the mean peak 
currents ± SEM (n=6-14). 
 
Fig. 4. Valerenic acid (10 μM) increases the peak amplitude of GABAergic mIPSCs 
without affecting their kinetics in cultured hippocampal neurons. (A) Averaged and 
superimposed mIPSCs (every trace represents the mean of at least 40 events) in 
control conditions (thin line) and in presence of Valerenic-acid (thick line). (B) 
Summary of the mIPSCs peak enhancement induced by valerenic acid (control, 37.5 
± 4.8 pA; valerenic acid, 53.1 ± 4.5 pA; mean ± SEM p<0.01, paired t-test, n = 7).  
 
Fig. 5. Behavioral effects of valerenic acid and valerenol in the light-dark choice test 
and the elevated plus-maze in mice. (A) Anxiolytic-like effects of valerenic acid (1, 3 
and 6 mg/kg given ip 15 min before test) in the light-dark choice test. At all doses 
tested, valerenic acid treatment increased the proportion of time 129/SvJ mice spent 
in the lit area during the 5-min test session (ANOVA, F(3, 30) = 7.14, P < 0.001, n = 
8-9 per group). (B) Likewise, valerenol administered ip at the dose range of 1-30 
mg/kg decreased significantly the aversion to the lit area (F(3, 25) = 12.42, P < 
0.001, n = 7-8 per group). (C) Oral administration of valerenic acid at the dose of 10 
mg/kg was effective in reducing the aversion to the lit area (U = 6, p < 0.05 as 
compared to vehicle, Mann-Whitney, n = 5-8 per group). (D) Valerenol administered 
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orally at the doses of 1 and 10 mg/kg increased the proportion of time spent in the lit 
area; this effect achieved significance at the dose of 1 mg/kg (F(2, 17) = 3.68, P < 
0.05, n = 6-7 per group). (E) In the elevated plus-maze, valerenic acid treatment (10 
mg/kg orally) increased significantly the proportion of time 129/SvJ mice spent onto 
the open arms (U = 34, p < 0.05, n = 11-12 per group). (F) Mice containing the 
β3(N265M) mutation failed to display the anti-aversive effect of valerenic acid (3 
mg/kg ip) (U = 26, not significant, n = 7-8 mice per group) as tested in the light/dark 
test. Nevertheless, diazepam (1.5 mg/kg ip) enhanced the time spent in the lit area in 
the β3(N265M) mice compared to vehicle (U = 13, p < 0.05, n = 8-9 per group). 
Results are expressed as means ± SEM Veh, Vehicle. *, p < 0.05, **, p < 0.01 as 
compared to vehicle, Dunnett’s tests after ANOVA, Mann-Whitney (U) tests. 
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